These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 20856855

  • 1. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.
    PLoS One; 2010 Sep 14; 5(9):e12417. PubMed ID: 20856855
    [Abstract] [Full Text] [Related]

  • 2. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM, Wei TT, Tang YA, Huang SM, Wen WL, Chen MY, Cheng HC, Salunke SB, Chen CS, Lin P, Chen CT, Wang YC.
    PLoS One; 2012 Sep 14; 7(1):e30240. PubMed ID: 22279574
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
    Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS.
    Hepatology; 2007 Oct 14; 46(4):1119-30. PubMed ID: 17654699
    [Abstract] [Full Text] [Related]

  • 4. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
    Piao J, Chen L, Quan T, Li L, Quan C, Piao Y, Jin T, Lin Z.
    Oncotarget; 2016 Sep 13; 7(37):60169-60180. PubMed ID: 27507059
    [Abstract] [Full Text] [Related]

  • 5. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J, Shivarudraiah P, Gavara G, Annamalai P, Natesan S, Sambasivam G, Sukumaran SK.
    Anticancer Res; 2015 Jan 13; 35(1):229-37. PubMed ID: 25550555
    [Abstract] [Full Text] [Related]

  • 6. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
    Shieh JM, Tang YA, Hu FH, Huang WJ, Wang YJ, Jen J, Liao SY, Lu YH, Yeh YL, Wang TW, Lin P, Wang YC.
    Int J Cancer; 2017 May 15; 140(10):2375-2386. PubMed ID: 28233309
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
    Singh T, Prasad R, Katiyar SK.
    Epigenetics; 2013 Jan 15; 8(1):54-65. PubMed ID: 23221619
    [Abstract] [Full Text] [Related]

  • 8. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
    Liu Y, Tong Y, Yang X, Li F, Zheng L, Liu W, Wu J, Ou R, Zhang G, Hu M, Liu Z, Lu L.
    Pharmacol Res; 2016 Sep 15; 111():113-125. PubMed ID: 27268146
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.
    Clin Cancer Res; 2006 Sep 01; 12(17):5199-206. PubMed ID: 16951239
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
    Wei Y, Zhou F, Lin Z, Shi L, Huang A, Liu T, Yu D, Wu G.
    Anticancer Drugs; 2018 Mar 01; 29(3):262-270. PubMed ID: 29356692
    [Abstract] [Full Text] [Related]

  • 11. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M, Dosaka-Akita H.
    Cancer Sci; 2016 Jul 01; 107(7):955-62. PubMed ID: 27116120
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
    Kisseberth WC, Murahari S, London CA, Kulp SK, Chen CS.
    Am J Vet Res; 2008 Jul 01; 69(7):938-45. PubMed ID: 18593248
    [Abstract] [Full Text] [Related]

  • 13. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.
    Mol Cancer Ther; 2008 Apr 01; 7(4):759-68. PubMed ID: 18413790
    [Abstract] [Full Text] [Related]

  • 14. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K.
    Lung Cancer; 2013 Nov 01; 82(2):214-21. PubMed ID: 24051085
    [Abstract] [Full Text] [Related]

  • 15. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y, Yu D, Wu H, Liu H, Zhou H, Gu R, Zhang R, Zhang S, Wu G.
    Int J Oncol; 2014 Feb 01; 44(2):451-8. PubMed ID: 24297449
    [Abstract] [Full Text] [Related]

  • 16. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC, Heo JH, Jeon JY, Choi HJ, Jo AR, Kim SW, Kwon HJ, Hong SJ, Han KS.
    BMC Cancer; 2015 Jan 23; 15():19. PubMed ID: 25613585
    [Abstract] [Full Text] [Related]

  • 17. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G, Gekeler V, Leja A, Beckers T, Boehm M.
    Cancer Res; 2006 May 15; 66(10):5409-18. PubMed ID: 16707469
    [Abstract] [Full Text] [Related]

  • 18. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.
    Wang L, Syn NL, Subhash VV, Any Y, Thuya WL, Cheow ESH, Kong L, Yu F, Peethala PC, Wong AL, Laljibhai HJ, Chinnathambi A, Ong PS, Ho PC, Sethi G, Yong WP, Goh BC.
    Cancer Lett; 2018 Mar 28; 417():152-160. PubMed ID: 29306016
    [Abstract] [Full Text] [Related]

  • 19. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
    Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG.
    Cancer Immunol Immunother; 2018 Mar 28; 67(3):381-392. PubMed ID: 29124315
    [Abstract] [Full Text] [Related]

  • 20. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS, Lee SC, Min HY, Park KH, Hyun SY, Kwon SJ, Choi SP, Kim WY, Lee HJ, Lee HY.
    Cancer Lett; 2015 Jun 01; 361(2):197-206. PubMed ID: 25721083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.